See the DrugPatentWatch profile for vascepa

Based on the information available, there is no definitive evidence to suggest that Vascepa (icosapent ethyl) increases the effectiveness of blood thinners.

Vascepa is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to lower the risk of heart attacks and strokes in people with triglyceride levels of 150 milligrams per deciliter or higher [1]. It is a type of omega-3 fatty acid.

Blood thinners, also known as anticoagulants, are medications that help prevent blood clots from forming [2]. They work by prolonging the time it takes for blood to clot.

While both Vascepa and blood thinners are used to reduce the risk of cardiovascular events, they have different mechanisms of action. Vascepa reduces the production of triglycerides, while blood thinners prevent the formation of blood clots. There is no published research or clinical trials indicating that Vascepa increases the effectiveness of blood thinners.

It is essential to consult with a healthcare provider before combining any medications, including Vascepa and blood thinners, to ensure safety and effectiveness.

Sources:
[1] "Vascepa (icosapent ethyl) Capsules, for Oral Use." U.S. Food and Drug Administration, FDA, 2021, www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/vascepa-icosapent-ethyl-capsules-oral-use.
[2] "Blood Thinners." Mayo Clinic, Mayo Foundation for Medical Education and Research, 15 Jan. 2021, www.mayoclinic.org/tests-procedures/blood-thinners/about/pac-20385144.
[3] "Icosapent Ethyl (Vascepa) for Hypertriglyceridemia." DrugPatentWatch, 2021, www.drugpatentwatch.com/drugs/icosapent-ethyl.